Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.46 |
| ▸ | RARG | P13631 | 4/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 3/20 | 0.39 |
| ▸ | FEN1 | P39748 | 10/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015536 | 0.91 | RARG (0.56) | RARBRARGRXRAHSD17B1HSD17B2 | |
| SCHEMBL19794505 | 0.87 | RARG (0.43) | RARBRARGRXRARARAFEN1 | |
| SCHEMBL21202890 | 0.86 | RARG (0.56) | RARBRARGRXRAHSD17B1HSD17B2 | |
| SCHEMBL19794384 | 0.86 | LDHA (0.40) | RARBRARGRXRAHSD17B1HSD17B2 | |
| SCHEMBL19794375 | 0.84 | RARG (0.40) | RARBRARGRXRARARAFEN1 | |
| SCHEMBL18015489 | 0.84 | ALOX5 (0.41) | RARBRARGRXRAHSD17B1HSD17B2 | |
| SCHEMBL18015538 | 0.83 | RARG (0.34) | RARBRARGRXRA | |
| SCHEMBL19794369 | 0.81 | HSD17B1 (0.43) | RARBRARGRXRAHSD17B1HSD17B2 | |
| SCHEMBL19794437 | 0.81 | LDHA (0.42) | RARBRARGRXRARARABACE1 | |
| SCHEMBL17486329 | 0.81 | RARB (0.42) | RARBRARGRXRAHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | RARB 2999/4885RARG 3090/4885RXRA 2518/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | RARB 3726/4885RARG 3136/4885RXRA 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.